Presentation
Efficacy and Safety of Talazoparib Versus Physician's Choice of Chemotherapy in US Patients with HER2-negative Germline BRCA1/2-Mutated (gBRCAm) Locally Advanced/Metastatic Breast Cancer (EMBRACA)
Metastatic Breast Cancer Conference
(2020)
Abstract
S. Diab; H.S. Rugo; L.A. Mina; S. Puhalla; N.L. Henry; N. Denduluri; D. Yardley; Y. Wang; L. Shahied Arruda; I.C. Tudor; E. Gauthier. A, Czibere; J.K. Litton; S. Hurvitz
Disciplines
Publication Date
2020
Citation Information
Reshma Mahtani. "Efficacy and Safety of Talazoparib Versus Physician's Choice of Chemotherapy in US Patients with HER2-negative Germline BRCA1/2-Mutated (gBRCAm) Locally Advanced/Metastatic Breast Cancer (EMBRACA)" Metastatic Breast Cancer Conference (2020) Available at: http://works.bepress.com/reshma-mahtani/33/